icon- folder.gif   Conference Reports for NATAP  
 
  21st Conference on Retroviruses and
Opportunistic Infections
Boston, MA March 3 - 6, 2014
 Back grey_arrow_rt.gif
 
 
 
HCV Coverage at CROI
 
 
  HCV Coverage at CROI
 
  • Ritonavir-Boosted Atazanavir, Lopinavir, & Darunavir Increase HCV NS5A Inhibitor MK-8742 Levels - (04/05/14)
     
  • Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 and Tenofovir (TDF), Raltegravir (RAL), and Efavirenz (EFV) - (04/05/14)
     
  • Daclatasvir Pharmacokinetics in Healthy Subjects: No Clinically Relevant Drug-Drug Interaction With Either Cyclosporine or Tacrolimus - (04/03/14)
     
  • CD4:CD8 Ratio Remains Significantly Depressed Despite Viral Suppression With Effective ART - (04/02/14)
     
  • Favorable Adverse Event Profile of Sofosbuvir/Ribavirin Versus Standard of Care for Hepatitis C - (04/02/14)
     
  • Summary from CROI 2014 for Hepatitis HCV direct acting antivirals (DAAs) in HCV and HIV/HCV coinfection: same outcome? Which DAA regime will allow for the shortest treatment duration? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/20/14)
     
  • The CORE HCV Cascade a Decade Later: Looking Ahead to an IFN-free Era - (03/24/14)
     
  • High Hepatitis C Infection Rate in Birth Cohort Testing of an Urban, Primary Care Clinic Population: HCV Cascade, 8.2% Prevalence - (03/24/14)
     
  • Impact of Rapid Hepatitis C testing on Receipt of Hepatitis C Results in a Public STD Clinic - (03/24/14)
     
  • The burden of hepatitis C infection in Pennsylvania state prisons and implications for treatment - (03/24/14)
     
  • Hepatitis C Virus Incidence in the Amsterdam Cohort Study among Men who have Sex with Men; 1984-2011 - (03/24/14)
     
  • The Treatment Cascade for People with Chronic Hepatitis C Virus Infection in the United States - (03/24/14)
     
  • Implementation of a Hepatitis C testing program in a network of Federally Qualified Health Centers: initial results of an Academic-Community partnership - (03/24/14)
     
  • The Hepatitis C Cascade of Care Among HIV Infected Patients Following Diagnosis of HCV Infection - (03/24/14)
     
  • CROI 2014 March 3 - Martin Delaney Panel: Hepatitis C Virus: From Trials and Tribulation to Triumph - (03/24/14)
     
  • Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14)
     
  • Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14)
     
  • Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals - (03/24/14)
     
  • Level of Alcohol Use and Advanced Hepatic Fibrosis in HIV-Infected and Uninfected Patients...."there may be no safe level of alcohol use among HIV+ & HCV+" - (03/24/14)
     
  • Pill Burden and Treatment Duration Reduce Adherence to IFN-Free Hepatitis C Therapy in an Urban Cohort - (03/24/14)
     
  • Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH) - (03/24/14)
     
  • Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial - (03/24/14)
     
  • Boceprevir/Telaprevir-Based Therapy in HIV-Infection: Interim Analysis of a Multicenter Cohort - (03/24/14)
     
  • Telaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients - (03/24/14)
     
  • PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14)
     
  • EFFECT OF FALDAPREVIR ON ATAZANAVIR PHARMACOKINETICS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14)
     
  • EFFECT OF FALDAPREVIR ON RALTEGRAVIR PHARMACOKINETICS IN HEALTHY VOLUNTEERS - (03/21/14)
     
  • FIB-4 Alone Proves Best Predictor of ESLD in People With HCV/HIV - written Mark Mascolini - (03/21/14)
     
  • Post-SVR Liver Decompensation Rate Similar With HCV/HIV and HCV Alone - written Mark Mascolini - (03/21/14)
     
  • Post-Transplant Survival Lower With HIV and HCV-1 Than With HCV-1 Alone - written by Mark Mascolini - (03/12/14)
     
  • Abbvie IFN-free 3 DAA Regimen in HCV Genotype 1-infected Patients on Methadone or Buprenorphine - (03/06/14)
     
  • On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - (03/06/14)
     
  • Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir; New Drug Application Accepted by FDA - (03/06/14)
     
  • Sofosbuvir With Ribavirin in Gt1/2/3 HCV/HIV Coinfected Patients - written by Mark Mascolini - (03/05/14)
     
  • HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM - written by Mark Mascolini - (03/05/14)
     
  • CROI: ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage - (03/05/14)
     
  • CROI: ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance - (03/05/14)
     
  • CROI: Triple-DAA Combo (a Possible 3-in-1 Pill) Yields SVRs Over 90% After 12 Weeks - written by Mark Mascolini - (03/05/14)
     
  • CROI: All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection - (03/04/14)
     
  • Daclatasvir in Combination With Simeprevir With or Without Ribavirin for Hepatitis C Virus Genotype 1 Infection - (03/04/14)
     
  • All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (03/04/14)
     
  • Three-DAA Regimen (Abbvie) Achieves 99% SVR12 Rates in HCV Genotype 1b Naives - written by Mark Mascolini - (03/04/14)
     
  • Simeprevir Plus PegIFN/RBV Yields 74% SVR12 in HCV/HIV Patients - written by Mark Mascolini - (03/04/14)
     
  • SVR12 72% With Faldaprevir Plus PegIFN/RBV in Naives With HCV/HIV - written by Mark Mascolini - (03/04/14)
     
  • Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Results of the SYNERGY Trial - (03/04/14)
     
  • Simeprevir plus PegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212) - (03/04/14)
     
  • Double or Triple DAA Therapy for HCV-1 Yields 95-100% SVRs in 6 or 12 Weeks (SYNERGY Study) - written by Mark Mascolini - (03/04/14)
     
  • PEARL III: SVR ≥99% AFTER 12 WKS OF ABT-450/R/267 + ABT-333 ± RBV IN TREATMENT-NAIVE HCV GT1B INFECTION - (03/04/14)
     

    •